Table 1.
EUCAST definitions of clinical breakpoints issued by the 2017 European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the number of isolates studied.
| EUCAST breakpoints* |
Resistance of the samples collected from the carriers |
|||
|---|---|---|---|---|
| Antibiotic | S ≤ mg/L | R > Mg/L | S N (%) | R N (%) |
| Penicillin | 0.125 | 0.125 | 99 (12.9) | 666 (87.1) |
| Oxacillin | 0.25 | 2 | 755 (98.7) | 10 (1.3) |
| Erythromycin | 1 | 2 | 679 (88.8) | 86 (11.2) |
| Azithromycin | 1 | 2 | 676 (88.4) | 89 (11.6) |
| Clindamycin | 0.25 | 0.5 | 691 (90.3) | 74 (9.7) |
| Ciprofloxacin1 | 1 | 1 | 747 (97.6) | 18 (2.4) |
| Gentamicin | 1 | 1 | 757 (99.0) | 8 (1.0) |
| Tetracycline | 1 | 2 | 751 (98.2) | 14 (1.8) |
| Vancomycin | 2 | 2 | 765 (100) | 0 (-) |
| Linezolid | 4 | 4 | 765 (100) | 0 (-) |
| Daptomycin | 1 | 1 | 765 (100) | 0 (-) |
S = susceptible; R = resistant.
*
The figures correspond to the minimal inhibitory concentrations (MIC) in mg/L above, which germs are considered as resistant.
1
Breakpoints are based on high dose therapy (750 mg ×2).